

1 **Antimalarial Drug Resistance Profiling of *Plasmodium falciparum* Infections**
2 **in India Using Next-Generation Sequencing**

3

4 Sonal Kale^{1,2*}, Swapna M. Uplekar^{3*}, Nabamita Bandyopadhyay^{1*}, Pavitra N. Rao^{3*}, Syed Z.
5 Ali⁴, S.K. Sharma⁴, Nikunj Tandel⁵, Ankita Patel⁵, Ranvir Singh⁵, Aaron Dank⁵, Sangamithra
6 Ravishankaran⁶, G Sri Lakshmi Priya⁶, Aswin Asokan⁶, Alex Eapen⁶, Om. P. Singh¹, Jane M.
7 Carlton^{3**}, Prashant K. Mallick¹

8

9

10 ¹ National Institute of Malaria Research, Indian Council of Medical Research, Sector 8, Dwarka,
11 New Delhi, India

12 ² Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and
13 Infectious Disease, NIH, Bethesda, Maryland, USA

14 ³ Center for Genomics and Systems Biology, Department of Biology, New York University, New
15 York, NY, USA

16 ⁴ National Institute of Malaria Research Field Unit, Sector 1 Health Center, Rourkela, Odisha,
17 India

18 ⁵ National Institute of Malaria Research Field Unit, Civil Hospital, Nadiad, Gujarat, India

19 ⁶ National Institute of Malaria Research Field Unit, Indian Council of Medical Research,
20 National Institute of Epidemiology Campus, Ayapakkam, Chennai, Tamil Nadu, India

21

22 *Authors contributed equally

23 ** Correspondence: J. M. Carlton, New York University, New York, NY 10003
24 (jane.carlton@nyu.edu)

25

26

27

28

29

30 **Abstract**

31

32 **Background:** Tracking the emergence and spread of antimalarial drug resistance has become
33 critical to sustaining progress towards the control and eventual elimination of malaria in South
34 Asia, especially India.

35 **Methods:** An amplicon sequencing protocol was used for high-throughput molecular
36 surveillance of antimalarial drug resistance in a total of 158 isolates at three sites in India:
37 Chennai, Nadiad and Rourkela. Five genes of the *Plasmodium falciparum* implicated in
38 antimalarial resistance were investigated here; *Pfcr1* for chloroquine resistance, *Pfdhfr* for
39 pyrimethamine resistance, *Pfdhps* for sulfadoxine resistance, *Pfk13* for artemisinin resistance and
40 *Pfmdr1* for resistance to multiple antimalarials.

41 **Results:** Mutations in the propeller domain of PfK13 were observed in two samples only,
42 however these mutations are not validated for artemisinin resistance. A high proportion of
43 parasites from the *P. falciparum* dominant site Rourkela showed wild-type *Pfcr1* and *Pfdhfr*
44 haplotypes, while mutant *Pfcr1* and *Pfdhfr* haplotypes were fixed at the *P. vivax* dominant sites
45 Chennai and Nadiad. The wild-type PfDHPS haplotype was predominant across all study sites.
46 Finally, we observed the largest proportion of suspected multi-clonal infections at Rourkela,
47 which has the highest transmission of *P. falciparum* among our study sites.

48

49 **Conclusion:** This is the first simultaneous high-throughput next generation sequencing of five
50 complete *P. falciparum* genes from infected patients in India.

51

52 **Keywords:** India, *Plasmodium falciparum*, antimalarial drug resistance, deep sequencing,
53 genomic

54

55

56

57 **Background**

58
59 Malaria remains a major cause of mortality and morbidity in tropical and sub-tropical countries.
60 In 2015, Africa had the greatest malaria burden with 88% of global malaria cases, followed by
61 Southeast Asia with 10%, and the eastern Mediterranean region with 2% [1]. India reported 1.2
62 million microscopy-confirmed cases of malaria and 384 deaths due to malaria in 2015,
63 accounting for approximately 89% of malaria cases in South East Asia and 6% of the total
64 malaria cases in the world [2]. Over 60% cases in India are caused by *Plasmodium falciparum*.
65 Massive efforts by a worldwide malaria elimination program have reduced the number of
66 malaria cases from 2010 by 12% to 214 million in year 2015, and reduced the number of malaria
67 deaths by 21% [3]. India has also joined malaria elimination efforts, allocating financial
68 resources and infrastructure for the launch of a ‘National Framework for Malaria Elimination in
69 India 2016-2030’ [1, 4]. This effort includes all Indian states with varying levels of malaria
70 transmission and outlines specific strategies to achieve the following milestones: 1) eliminate
71 malaria throughout the entire country by 2030; and 2) maintain a malaria-free status in areas
72 where transmission has been interrupted and prevent re-introduction of malaria.

73
74 The emergence and spread of parasite resistance against available antimalarials constitutes a
75 major threat towards the efforts of the elimination program, as evidenced by the reversal of
76 previous malaria eradication successes to failure [5]. Routine molecular surveillance of parasite
77 strains is an essential tool for identifying and limiting the spread of emerging antimalarial
78 resistance. Sanger sequencing is the gold standard for validation of genotypes identified in
79 parasite clinical isolates, but sensitivity and scalability remain limiting factors; these may be
80 overcome by high-throughput next generation sequencing (NGS) that facilitates the generation of

81 massive amounts of genomic data in a relatively short time by parallelization of sequencing
82 reactions. The technology provides high sequencing coverage, which enables the detection of
83 low-frequency mutations relevant to drug resistance, or low frequency wild-type parasites arising
84 after reversion of mutant genotypes following antimalarial withdrawal from a region. NGS can
85 also provide deep insight into genetic diversity of heterogeneous parasite populations.

86
87 We have previously described a novel amplicon sequencing protocol for high throughput
88 molecular surveillance of drug resistance in field settings [6]. This protocol identifies
89 polymorphisms in five important genes implicated in *P. falciparum* resistance against the
90 mainstay antimalarials; *Pfcr1* for chloroquine resistance, *Pfdhfr* for pyrimethamine resistance,
91 *Pfdhps* for sulfadoxine resistance, *Pfk13* for artemisinin resistance and *Pfmdr1* for resistance to
92 multiple antimalarials. The Center for the Study of Complex Malaria in India (CSCMI) was
93 established in 2010, with the aim of elucidating the epidemiology and transmission of malaria in
94 India at three ecologically diverse sites - Chennai, Nadiad and Rourkela [7]. In this study, we
95 have implemented the aforementioned amplicon-sequencing protocol in field settings to
96 elucidate genomic landscapes of drug resistance at these three CSCMI study sites representing
97 varying transmission ecologies. To our knowledge, this is the first study providing status of
98 multiple drug resistance genotypes at these sites.

99

100 **METHODS**

101

102

103 **Malaria epidemiology of study sites**

104

105 Chennai, located on the eastern coast of India is the capital city of Tamil Nadu state, and had

106 over 7 million inhabitants in 2011. Chennai accounts for 55.6% of all malaria cases in Tamil

107 Nadu, which had an annual parasite index (API) of 0.12 in 2014 [4, 8]. Malaria is hypo-endemic
108 in Chennai, and *P. vivax* is the dominant species. Subjects were enrolled at the Besant Nagar
109 Malaria Clinic, or in cross-sectional surveys conducted in the Besant Nagar catchment area.
110 Nadiad, located in the Kheda district in Gujarat state (API in 2014: 0.66), had a population of 0.2
111 million in 2011. Nadiad is hypo-endemic for malaria, with slightly higher prevalence of *P. vivax*
112 than *P. falciparum*. Subjects were enrolled at either the NIMR malaria clinic in Nadiad Civil
113 Hospital or at an urban health center in the Vatva ward of Ahmedabad city, the capital of Gujarat
114 state. Alternately, subjects were enrolled in cross-sectional surveys conducted in the vicinity of
115 Nadiad town. Rourkela, located in Sundargarh district close to the northern border of the state of
116 Odisha (API in 2014: 9.08), had a population of over 0.5 million in 2011. Rourkela has meso-to-
117 hyperendemic transmission of malaria, with *P. falciparum* as the dominant species. Subjects
118 were enrolled at a health center clinic set up in a suburb of Rourkela, and in cross-sectional
119 surveys conducted in rural areas around Rourkela.

120 121 **Sample collection and processing**

122
123 158 of 300 *P. falciparum* isolates collected as part of the CSCMi study [7] and tested using our
124 amplicon sequencing protocol [6] were sequenced successfully, with amplification failing in
125 isolates with poor quality or low concentration of DNA. These isolates were collected from 141
126 study enrollees at three sites: Chennai (18 isolates from 15 patients), Nadiad (55 isolates from 41
127 patients) and Rourkela (85 isolates from 85 patients), between December 2012 and September
128 2015 (**Table 1**). A majority of the enrollees were male (98 male, 43 female). Patients were
129 between 2-69 years old, with a mean age of 27.44 (95%CI: 24.83-30.07). Asexual or sexual *P.*
130 *falciparum* parasitemia was detectable by microscopy in 140 isolates, with a mean parasitemia of
131 14073.16 parasites/ul (95%CI: 3822.15- 24324.18); 18 isolates were submicroscopic. 149

132 isolates were positive for *Plasmodium falciparum* species-specific PCR, 9 were PCR negative.
133 Patients were enrolled after obtaining informed consent, and treated with antimalarials as per the
134 Indian national guidelines [9].

135
136 **DNA extraction, library preparation and sequencing**
137

138 DNA was extracted from *P. falciparum*-infected blood samples collected on Whatman filter
139 paper, small EDTA microvettes or EDTA vacutainers using QIAamp DNA Blood Mini or Midi
140 Kit (Qiagen Inc., catalog nos. 51106, 51185) after separation of plasma, and 1-5 ul was used as a
141 template for amplicon synthesis. Primers and PCR conditions were as outlined in [6]. For each
142 sample, 10 ul of every amplicon was pooled, and the pooled mixture was purified using the
143 QIAquick PCR Purification Kit (Qiagen Inc., catalog no. 28106) and quantitated using a Qubit
144 2.0 fluorometer (Thermo Fisher Scientific, catalog no. Q32866). Barcoded sequencing libraries
145 were generated from 100-500 ng of purified pooled PCR product using ion expressTM barcode
146 adapters (Life Technologies, catalog no. 4471250 for barcodes 1-16; catalog no. 4474009 for
147 barcodes 17-32) and library prep kit (New England Biolabs, catalog no. E6285L). The size and
148 quality of libraries were determined using an Agilent bioanalyzer, and quantified by quantitative
149 PCR using Ion Torrent Library Quantification kit (KK4857, KAPA biosystems) on a
150 LightCycler^R 480 (Roche). For most experiments, 16 barcoded libraries were pooled for a single
151 run on the PGM using Ion PGMTM Hi-QTM sequencing technology and IonTM 314v2 type chips,
152 except for one library pool that was run on an IonTM 318v2 chip. Genomic DNA from *P.*
153 *falciparum* strains Dd2 (MRA-150G) and 7G8 (MRA-152G) was obtained from the Malaria
154 Research and Reference Reagents Resource (MR4). Control libraries prepared with Dd2 or 7G8
155 DNA were included in each run. We also sequenced ten additional *P. falciparum* reference
156 strains (NF54 E, TM91C235, HB3, W2, K1, V1/S, D10, GB4, D6, FCB) as part of different runs

157 to ensure that our variant calling results showed complete concordance with previously published
158 data for these isolates.

159
160 **Data processing**

161
162 Sequencing data were analyzed using the Ion Torrent platform software (Torrent Suite 5.0.2).
163 Raw reads were de-multiplexed and filtered using standard quality filtering parameters by
164 Torrent Suite pipeline software. Read quality was assessed using the Torrent Suite FastQC
165 plugin v0.10.1, and high-quality reads were aligned to the reference using the Torrent Mapping
166 Alignment Program v5.0. The reference data file used was a multi-FASTA file containing the
167 complete gene sequence and 300bp flanking regions for each amplicon target gene from the *P.*
168 *falciparum* 3D7 genome using the PlasmoDB database .

169
170 **Data analysis**

171
172 Variant calling was performed with low stringency parameters using the Ion Torrent Variant
173 Caller plugin (v5.0). We generated a list of all positions in all genes that were variable in at least
174 one sample; for samples where no variants were reported at these positions, the presence of the
175 reference allele was confirmed by obtaining raw nucleotide counts and quality scores from
176 corresponding BAM files using BEDTools . Variant filtering criteria was determined based on
177 the quality of known SNPs in MR4 reference isolates sequenced in each run. Variant calls with
178 SNP allele depth < 10 reads and base quality score < 10 were discarded. Calls with SNP allele
179 frequency between 20% - 80% were marked as heterozygous and subsequently used to classify
180 samples as multi-clonal infections, i.e. containing more than one distinct parasite genotype. SNP
181 calls were processed to determine codon changes based on the *P. falciparum* 3D7 gene
182 annotation from the PlasmoDB database using custom Perl and MS Excel VBA scripts. In the

183 case of multiple nucleotide polymorphisms (MNPs) affecting the same codon, if both SNP
184 alleles occur at a frequency > 80%, they were merged to calculate the resulting codon change;
185 variant calls with SNP allele frequency < 20% were discarded. For the *Pfcr*t gene, MNPs
186 affecting codon positions 72-76 were filtered using a higher SNP allele frequency cut-off of
187 30%. A high proportion of homo-polymer repeats in the *Pfcr*t gene led to poor sequencing
188 quality misalignment of reads. As a result variants in this gene were manually curated using the
189 IGV genome browser, particularly for the genomic locus corresponding to codons 72-76.
190 Population structure was examined using a non-model-based multivariate analysis method as
191 implemented in the adegenet 2.0.1 package using the *dudi.pca* function. In the case of multi-
192 allelic SNPs, the major allele call was used to represent the dominant genotype at that position.

193

194 **RESULTS**

195

196 We have successfully sequenced a panel of five *P. falciparum* genes implicated in antimalarial
197 drug resistance in clinical isolates from India using a previous validated amplicon sequencing
198 protocol [6]. *Pfk13*, *Pfcr*t, *Pfmdr1*, *Pfdhfr* and *Pfdhps* have been implicated in resistance to first-
199 line antimalarial therapy, including artemisinin combination therapy, chloroquine, and
200 sulfadoxine-pyrimethamine. We deduced SNP haplotypes from key resistance-associated alleles
201 in the target genes for 158 isolates collected at three sites in India. Implications of the resistance
202 mutations identified at the three sites have been described below in the context of each drug they
203 are associated with.

204

205 **Resistance to chloroquine**

206

207 Mutations encoding amino acid substitutions in the chloroquine resistance transporter PfCRT
208 (PF3D7_0709000) at positions 72, 74, 75, 76, 97, 220, 271, 326, 356 and 371 have been

209 associated with increased resistance to chloroquine (CQ), with the K76T substitution being the
210 primary mediator of resistance [10-12]. 147 of 158 isolates sequenced carried only one haplotype
211 at the PfCRT locus; one isolate had multiple PfCRT haplotypes, and 10 isolates had partial or
212 missing PfCRT haplotype data (**Table 2**). The CQ-resistant PfCRT haplotype S⁷²V⁷³M⁷⁴N⁷⁵T⁷⁶,
213 purported to be the most prevalent PfCRT haplotype in India [13], was present in 71/147
214 isolates, including all isolates from Chennai and most isolates from Nadiad, but only two isolates
215 from Rourkela. Contrastingly, the CQ-sensitive wild-type haplotype C⁷²V⁷³M⁷⁴N⁷⁵K⁷⁶ was
216 detected in 46 isolates from Rourkela, but absent from Nadiad and Chennai. The CQ-resistant
217 haplotype C⁷²V⁷³I⁷⁴E⁷⁵T⁷⁶ was present in 30/147 isolates: 28 isolates from Rourkela and 2
218 isolates from Nadiad. Both copy number variation and mutations encoding substitutions in the
219 multidrug resistance protein PfMDR1 (PF3D7_0523000) codons 86, 184, 1034, 1042 and 1246
220 can modulate resistance to various antimalarial drugs (summarized in [14]). While our protocol
221 does not permit gene copy number assessment, we were able to identify polymorphisms
222 associated with resistance to CQ. 129 of 158 isolates sequenced carried only one PfMDR1
223 haplotype, while 10 isolates possessed more than one PfMDR1 haplotype, which may be
224 attributed to increased *Pfmdr1* copy number (**Table 2**). 19 isolates had partial or missing
225 haplotype data. The single-mutant PfMDR1 haplotype N⁸⁶F¹⁸⁴S¹⁰³⁴N¹⁰⁴²D¹²⁴⁶ was predominant
226 (57/129) among isolates in our study, and the wild-type PfMDR1 haplotype
227 N⁸⁶Y¹⁸⁴S¹⁰³⁴N¹⁰⁴²D¹²⁴⁶ was also prevalent in several (45/129) isolates. Double-mutant PfMDR1
228 haplotypes were rare, with only 5/129 isolates containing the haplotypes Y⁸⁶F¹⁸⁴S¹⁰³⁴N¹⁰⁴²D¹²⁴⁶
229 or N⁸⁶F¹⁸⁴S¹⁰³⁴D¹⁰⁴²D¹²⁴⁶. The single mutation-bearing haplotype Y⁸⁶Y¹⁸⁴S¹⁰³⁴N¹⁰⁴²D¹²⁴⁶ was
230 present in 22/129 isolates, 11 each from Nadiad and Rourkela.

231 A total of 12 haplotype combinations between the PfCRT and PfMDR1 loci were seen in
232 122 isolates with complete sequence information for these genes across the three sites. Rourkela
233 had the largest diversity of haplotypes, with 10 haplotype combinations at these two loci, and
234 Chennai had the least diversity (**Table 3**), with only one haplotype combination. The PfCRT and
235 PfMDR1 haplotype combination of $S^{72}V^{73}M^{74}N^{75}T^{76} + N^{86}F^{184}S^{1034}N^{1042}D^{1246}$ was most common
236 among isolates surveyed in our study (47/122), but was seen primarily in Chennai and Nadiad
237 and not in Rourkela. The combination of wild-type haplotypes at both loci ($C^{72}V^{73}M^{74}N^{75}K^{76} +$
238 $N^{86}Y^{184}S^{1034}N^{1042}D^{1246}$) was seen only at Rourkela, and present in the highest proportion at that
239 site.

240

241 **Resistance to sulfadoxine-pyrimethamine**

242

243 Mutations encoding amino acid substitutions at positions 51, 59, 108, 164 in the enzyme
244 dihydrofolate reductase PfDHFR (PF3D7_0417200) are associated with increased resistance to
245 pyrimethamine (PYR), with the S108N mutation primarily responsible for resistance [15, 16].
246 137 of 158 isolates sequenced carried only a single haplotype at the PfDHFR locus; 12 isolates
247 carried multiple PfDHFR haplotypes and 9 isolates had partial or missing PfDHPS haplotype
248 data (**Table 2**). The double-mutant PfDHFR haplotype $A^{16}N^{51}R^{59}N^{108}I^{164}$ was most common
249 among isolates (99/137) in our study, while the single-mutant $A^{16}N^{51}C^{59}N^{108}I^{164}$ haplotype was
250 extremely rare (1/137); triple ($A^{16}I^{51}R^{59}N^{108}I^{164}$) or quadruple ($A^{16}I^{51}R^{59}N^{108}L^{164}$) mutant
251 haplotypes could not be detected. Several isolates (37/137) had only the PYR-sensitive wild-type
252 PfDHFR haplotype $A^{16}N^{51}C^{59}S^{108}I^{164}$. Resistance to sulfadoxine (SUL) has been associated with
253 mutations encoding amino acid substitutions at positions 436, 437, 540, 581 and 613 in the
254 enzyme dihydropteroate synthetase (PfDHPS), with the A437G substitution arising first [17, 18].

255 143 of 158 isolates sequenced carried only a single haplotype at the PfdHPS locus; 15 isolates
256 had partial or missing PfdHPS haplotype data. The SUL-sensitive wild-type PfdHPS haplotype
257 $S^{436}A^{437}K^{540}A^{581}A^{613}$ predominated in our study, with 134/143 isolates carrying only this
258 haplotype. Two isolates from Rourkela possessed the triple mutant PfdHPS haplotype
259 $A^{436}G^{437}E^{540}A^{581}A^{613}$, while the double mutant haplotype $S^{436}G^{437}E^{540}A^{581}A^{613}$ was only detected
260 in a single isolate. Six isolates carried the single-mutant $S^{436}G^{437}K^{540}A^{581}A^{613}$ haplotype.

261 A total of 5 haplotype combinations between the PfdHFR and PfdHPS loci were seen in
262 129 isolates with complete sequence information for these two genes across the three sites
263 (**Table 3**). The combination of double-mutant PfdHFR with wild-type PfdHPS
264 ($A^{16}N^{51}R^{59}N^{108}I^{164} + S^{436}A^{437}K^{540}A^{581}A^{613}$) was predominant among isolates in our study
265 (87/129). Two samples from Rourkela had the strongest predictors of treatment failure in our
266 dataset- the combination of double-mutant PfdHFR with triple-mutant PfdHPS
267 ($A^{16}N^{51}R^{59}N^{108}I^{164} + A^{436}G^{437}E^{540}A^{581}A^{613}$). Only 33 isolates, primarily from Rourkela, carried
268 wild-type haplotypes at both loci. Two other haplotype combinations were observed in the
269 population: ($A^{16}N^{51}R^{59}N^{108}I^{164} + S^{436}G^{437}K^{540}A^{581}A^{613}$), seen in six isolates and
270 ($A^{16}N^{51}C^{59}N^{108}I^{164} + S^{436}G^{437}E^{540}A^{581}A^{613}$) seen in one isolate.

271
272 **Resistance to artemisinin combination therapies**
273
274 Mutations in the propeller domain of the kelch protein PfK13 (PF3D7_1343700) have been
275 shown to be associated with resistance to artemisinin derivatives [19, 20], which is defined as a
276 delayed clearance of parasites from the blood following artemisinin administration [21]. The
277 *Pfk13* gene was completely conserved among 92/158 isolates that were successfully sequenced at
278 this locus, and a majority of the SNPs observed in the remaining isolates led to synonymous

279 changes (60/92 SNPs). Only 2 isolates had substitutions in the propeller domain: V555L in
280 N0319-V1, and A578S in R5025. We did not identify any of the four validated SNPs (C580Y,
281 R539T, I543T or Y493H) implicated in artemisinin resistance in our isolates [19, 22]. The
282 K189T mutation was seen in 17 isolates in our study, all from Rourkela. Mutations encoding
283 amino acid substitutions in PfCRT, (such as I356T) are part of the genetic background associated
284 with the emergence of artemisinin resistance [23], and were present in 20 isolates from our study
285 (18 from Rourkela, 2 from Nadiad).

286 Resistance to the artemisinin combination therapy (ACT) partner drugs lumefantrine, mefloquine
287 and piperaquine, has also been linked to certain PfCRT and PfMDR1 haplotypes. The wild type
288 PfCRT K76 allele, associated with lumefantrine tolerance [24], was present in 46/129 isolates,
289 all from Rourkela. The wild-type N86 allele of PfMDR1, associated with decreased
290 susceptibility to lumefantrine [25], was observed in 103 of a total of 129 isolates in our study
291 bearing only one PfMDR1 haplotype. The N⁸⁶F¹⁸⁴D¹²⁴⁶ haplotype, selected for after artemether-
292 lumefantrine (AL) treatment in Africa [26, 27], was observed in 58/129 isolates.

293

294 **Analysis of longitudinal Plasmodium samples from an individual**

295

296 For a few enrollees (14/141), drug resistance genes were sequenced from parasite isolates
297 collected on day 2, day 7 or day 14 following ACT treatment. Of these, three individuals were
298 from Chennai and eleven from Nadiad. A majority of the post-treatment follow-up samples had
299 drug resistance haplotypes that were identical to samples collected from the same patient on
300 enrollment (**Supplementary Table 2**). However, enrollee N0319 had a mixture of wild-type
301 (N⁸⁶Y¹⁸⁴S¹⁰³⁴N¹⁰⁴²D¹²⁴⁶) and mutant (Y⁸⁶F¹⁸⁴S¹⁰³⁴N¹⁰⁴²D¹²⁴⁶) PfMDR1 haplotypes on the day of
302 enrollment, but on day 2, only the mutant (Y⁸⁶F¹⁸⁴S¹⁰³⁴N¹⁰⁴²D¹²⁴⁶) haplotype could be detected

303 **(Supplementary Table 2)**. Most enrollees in our study did not have parasitemia detectable by
304 microscopy or PCR on day 2 following ACT treatment.

305

306 **Using heterozygous variants for COI estimation**

307

308 In order to identify possible multi-clonal infections among the clinical isolates, we ranked the
309 isolates based on the total number of high-quality heterozygous variants (i.e. positions containing
310 more than one allele), similar to [6] **(Figure 1)**. Isolates containing more than twice the median
311 number of heterozygous variants in the dataset were classified as potential multi-clonal
312 infections. This included 30 isolates in total, 8 from Nadiad and 22 from Rourkela
313 **(Supplementary Table 3)**. We did not identify any multiclonal infections in Chennai.

314

315 **Clustering of isolates based on drug resistance haplotypes**

316

317 In order to identify population-specific variation in the drug resistance genes we performed
318 principal component analysis (PCA) using sequence data at 230 polymorphic positions. The first
319 two principal components accounted for 49.1% of the variation in the SNP data (PC1=30.74%,
320 PC2=18.36%). The PCA showed isolates from Chennai and Nadiad clustering together, while
321 isolates from Raurkela were split into two separate clusters **(Figure 2a)**. Further analysis
322 revealed that the three clusters correspond to distinct PfCRT haplotypes (codons 72-76). The two
323 clusters of isolates from Raurkela were associated with haplotypes $C^{72}V^{73}I^{74}E^{75}T^{76}$ and
324 $C^{72}V^{73}M^{74}N^{75}K^{76}$, whereas the cluster containing isolates from Chennai and Nadiad was
325 associated with the $S^{72}V^{73}M^{74}N^{75}T^{76}$ haplotype. Depending on the specific PfCRT haplotype,
326 MR4 reference strains were placed across all three clusters **(Figure 2b)**.

327

328 **DISCUSSION**

329
330 Tracking the emergence and spread of antimalarial drug resistance has become critical to
331 sustaining progress towards the control and eventual elimination of malaria in South Asia,
332 especially India. *P. falciparum* has evolved resistance to virtually every drug introduced to
333 combat it, due to several factors such as substandard drug quality, improper prescription
334 practices, and consumption of drugs as mono-therapy instead of combination therapies.

335
336 Chloroquine (CQ) was widely used as an antimalarial across the world since the 1930s, due to its
337 high efficacy and relative inexpensiveness. In the 1950s CQ-resistant *P. falciparum* arose
338 simultaneously in South America and South East Asia; it was first detected in India by 1973 and
339 eventually spread through the country [28]. CQ remained the first-line therapy for *P. vivax*
340 infections in India, even after its use against *P. falciparum* was discontinued. Membrane
341 transporters such as PfCRT and PfMDR1 can acquire mutations that may modulate resistance to
342 CQ by reducing accumulation of CQ in the food vacuole [29]. We observed a diverse
343 distribution of three PfCRT and five PfMDR1 haplotypes in isolates across our study sites. The
344 CQ resistance-associated PfCRT S⁷²V⁷³M⁷⁴N⁷⁵T⁷⁶ haplotype was fixed in the Chennai and
345 Nadiad, while parasites in Rourkela possessed either the CQ resistance-associated PfCRT
346 C⁷²V⁷³I⁷⁴E⁷⁵T⁷⁶ haplotype or the CQ-sensitive, wild-type PfCRT C⁷²V⁷³M⁷⁴N⁷⁵K⁷⁶ haplotype.
347 Among the three study sites, Rourkela has the highest prevalence of *P. falciparum*, followed by
348 Nadiad and Chennai. Conversely, the prevalence of *P. vivax* is higher in Chennai and Nadiad,
349 leading to higher CQ usage and drug pressure, possibly explaining the expansion of the PfCRT
350 S⁷²V⁷³M⁷⁴N⁷⁵T⁷⁶ haplotype at these two sites. The S⁷²V⁷³M⁷⁴N⁷⁵T⁷⁶ haplotype from PNG [30,
351 31] may have been introduced to South India through Sri Lanka or the Andaman and Nicobar
352 Islands and subsequently spread through the rest of the country [32]. It is evident through the

353 PCA that the parasite population in Rourkela is split into two distinct clusters, corresponding to
354 CQ-resistant ($C^{72}V^{73}I^{74}E^{75}T^{76}$) and CQ-sensitive ($C^{72}V^{73}M^{74}N^{75}K^{76}$) haplotypes. While the
355 PfCRT $S^{72}V^{73}M^{74}N^{75}T^{76}$ haplotype is predominant in most of India, earlier studies have shown
356 that the eastern state of Orissa has a higher prevalence of the $C^{72}V^{73}I^{74}E^{75}T^{76}$ haplotype [33, 34].
357 The $C^{72}V^{73}I^{74}E^{75}T^{76}$ haplotype may have been introduced to Rourkela through North-East India,
358 following the well-established migratory route of South East Asian *P. falciparum* strains into
359 India. We propose that in the absence of CQ pressure in Rourkela, there is reversion to the wild-
360 type $C^{72}V^{73}M^{74}N^{75}K^{76}$ haplotype from the mutant $C^{72}V^{73}I^{74}E^{75}T^{76}$ haplotype as the fitness cost
361 associated with the $C^{72}V^{73}I^{74}E^{75}T^{76}$ haplotype may be greater than that of the $S^{72}V^{73}M^{74}N^{75}T^{76}$
362 haplotype [35]. CQ resistance can also be modulated by mutations in PfMDR1 when they occur
363 in the background of resistance-conferring mutations in PfCRT [35]. The PfMDR1 substitution
364 N86Y contributes to CQ-resistance but has been associated with sensitization of *P. falciparum*
365 parasites to dihydroartemisinin (DHA) and lumefantrine (LMF) [36]. We observed a
366 predominance of the PfMDR1 N86 allele and PfCRT $S^{72}V^{73}M^{74}N^{75}T^{76}$ haplotype in Chennai and
367 Nadiad, which corroborates with previous observations in regions of low *P. falciparum*
368 transmission in India by Mallick *et al* [37], who also identified a mixture of mutant and wild-
369 type haplotypes in high transmission regions.

370
371 Following widespread CQ resistance, a combination of the antifolates sulfadoxine and
372 pyrimethamine (SP) was introduced as the second-line antimalarial treatment for *P. falciparum*
373 in 1982. Resistance to sulfadoxine (SUL) and pyrimethamine (PYR) has been associated with
374 mutations in the folate biosynthesis pathway enzymes, *Pfdhps* and *Pfdhfr* respectively; it has
375 been proposed that these enzymes reduce binding of the antifolates to their targets. In our study,

376 the wild-type SUL-sensitive PfDHPS haplotype S⁴³⁶A⁴³⁷K⁵⁴⁰A⁵⁸¹A⁶¹³ was predominant across all
377 three sites, occurring primarily in combination with the PYR-resistant, double-mutant PfDHFR
378 haplotype A¹⁶N⁵¹R⁵⁹N¹⁰⁸I¹⁶⁴ in Nadiad and Chennai. However, at Rourkela, there were
379 comparable numbers of isolates with the wild type A¹⁶N⁵¹C⁵⁹S¹⁰⁸I¹⁶⁴ and double-mutant
380 A¹⁶N⁵¹R⁵⁹N¹⁰⁸I¹⁶⁴ DHFR haplotypes. The double mutant A¹⁶N⁵¹R⁵⁹N¹⁰⁸I¹⁶⁴ PfDHFR haplotype
381 was predominant at each site, corroborating with previous studies from India [34, 37]. We
382 primarily detect wild-type PfDHPS and double-mutant PfDHFR haplotypes, that confer no
383 resistance or low-level resistance to PYR and SUL, respectively. This observation coupled with
384 the absence of quadruple or quintuple mutant haplotypes at all three sites suggest that *P.*
385 *falciparum* resistance to SP therapy at these three sites is very low [37].

386
387 Artemisinin (ART) and its derivatives-artesunate, artemether, dihydroartemisinin are among the
388 most effective antimalarials currently available. Owing to their short half-lives in the blood, they
389 are administered in combination with partner drugs with longer half-lives, such as lumefantrine,
390 piperazine, etc., in order to kill residual parasites. Artemisinin combination therapy (ACT) was
391 recommended as first-line treatment for *P. falciparum* infections by the WHO in 2005. In most
392 parts of India artesunate is used in combination with sulfadoxine and pyrimethamine (AS-SP),
393 except for the North-East region where the combination of artemether and lumefantrine (AL) is
394 used instead, due to widespread SP resistance [9]. Artemisinin resistance was first identified in
395 Cambodia and spread quickly through South East Asia, while also emerging simultaneously at
396 different foci in South Asia. Mutations in the propeller domain of the kelch protein K13 were
397 shown to be associated with delayed clearance of parasites after ACT treatment [19, 20]. Since
398 K13 mutations were recently detected in an area of Myanmar that is adjacent to the eastern

399 border of India [38], there has been concern about the spread of artemisinin resistance into India,
400 in a manner similar to the previous spread of CQ and SP resistance. If artemisinin fails, there is
401 no drug with comparable efficacy to replace it. While ACT failure has been reported in North
402 East India, it may be attributed to failure of the partner drugs [39, 40], and studies examining the
403 propeller domain have not detected any mutations associated with resistance among Indian
404 isolates except F446I, which remains to be validated [41-43]. Our study identified two mutations
405 in the propeller region – one from an isolate in Nadiad, and the other from Rourkela. The V555L
406 substitution (seen in sample N0319-V1) has been detected in Senegal at a very low frequency
407 [44], while A578S (seen in R5025) has been detected in several isolates from Africa, India and
408 Bangladesh [22, 41, 42, 45]. Neither has been associated with resistance among field isolates or
409 in *in vitro* assays. The K189T mutation that was identified in a subset of the Rourkela population
410 has previously been seen in isolates from Senegal, Guyana, the China-Myanmar border, and
411 Northeast India [42, 46-48]. The wild-type N86 allele of PfMDR1 and the wild-type K76 allele
412 of PfCRT were selected after artemether-lumefantrine combination therapy in Africa [24-27] and
413 were associated with decreased susceptibility to lumefantrine *in vitro* [24]. Our data suggests that
414 AL treatment is likely be effective in areas with a predominance of CQ-resistant PfCRT
415 haplotypes S⁷²V⁷³M⁷⁴N⁷⁵T⁷⁶ (Chennai and Nadiad) and C⁷²V⁷³I⁷⁴E⁷⁵T⁷⁶ (Rourkela) as well as the
416 PfMDR1 haplotypes Y⁸⁶F¹⁸⁴S¹⁰³⁴N¹⁰⁴²D¹²⁴⁶ and Y⁸⁶Y¹⁸⁴S¹⁰³⁴N¹⁰⁴²D¹²⁴⁶ (Nadiad and Rourkela).
417
418 Parasite isolates from Rourkela showed greater diversity than isolates from Chennai and Nadiad
419 at all drug resistance loci. PCA clustering revealed that parasites from Chennai and Nadiad were
420 more closely related, whereas the parasites in Rourkela separated into two populations that were
421 associated with distinct PfCRT haplotypes. There was a near-equal distribution of wild-type and

422 mutant haplotypes at the *Pfcrt*, *Pfdhfr* and *Pfmdr1* loci in Rourkela. The eight isolates in our
423 dataset that possessed wild-type haplotypes at all the drug resistance loci were also from
424 Rourkela. Interestingly, over 70% of the potential multi-clonal infections identified were from
425 Rourkela, the remainder from Nadiad, and none were from Chennai. We suspect that as a result
426 of higher prevalence and transmission of *P. falciparum* in Rourkela, the complexity of infection
427 may be higher at this site, compared to Nadiad or Chennai, where the prevalence of *P.*
428 *falciparum* is much lower.

429
430 We have demonstrated the potential of amplicon sequencing to discriminate between single- and
431 multi-clonal infections. Another application of this method is to study the variation in within-
432 host diversity in response to chemotherapy. This is particularly interesting for multi-clonal
433 infections as it can enable us to track changes in the frequency of individual alleles before and
434 after drug treatment [49]. Our analysis of parasite isolates from follow-up (collected after ACT-
435 treatment) samples was limited to a small number of samples from Chennai and Nadiad. For all
436 pairs of isolates collected from same individual, the key drug resistance SNPs were identical
437 enrollment and follow-up isolates, except in the case of one patient isolate in Nadiad (N0319)
438 that possessed a mixture of CQ-resistant and CQ-sensitive haplotypes at the *Pfmdr1* locus at
439 enrollment, but retained only the CQ-resistant haplotype following drug treatment. The potential
440 multi-clonal infections identified in our study did not include any pairs of follow-up isolates,
441 mainly because we did not have any follow-up samples collected in Rourkela. The likelihood of
442 the pretreatment infection being multi-clonal is much lower in Chennai and Nadiad, compared to
443 Rourkela because of lower COI. Therefore, it is not surprising that we identified the same
444 parasite haplotypes in patients, pre-and post-ACT administration.

445

446 We have established amplicon sequencing as an important tool for high-throughput molecular
447 surveillance of antimalarial drug resistance in India, especially since it can be implemented in
448 field settings, as we have demonstrated in this study.

449

450 **Abbreviations**

451 **MSP-1₁₉**: merozoite surface protein-1₁₉

452 **AMA-1**: apical membrane antigen-1

453

454 **Declarations**

455 **Ethics approval and consent to participate**

456 Ethical approval to conduct this study was obtained from New York University Institutional
457 Review Board (Study #i10-00173) and the Ethics Committee of the National Institute of Malaria
458 Research, India (ICMR). All project staff completed Protection of Human Research Subjects
459 training prior to beginning the study, and clinical samples were collected after informed consent
460 was obtained from all participants.

461

462 **Author's Contributions**

463 JMC, OPS, PKM, designed the study. OPS, JMC, PKM contributed reagents/materials/analysis
464 tools. AA, SR, SLPG, NT, SZA, HCS, SKS, AE contributed in sample collection and processing.
465 SK, NB performed the experiments. SK, SU, PR, PKM analyzed and interpreted data. SK, SU,
466 PR wrote the first draft. PKM, OPS, JMC reviewed and edited the manuscript. All authors read
467 and approved the final manuscript.

468

469 **Acknowledgments**

470 We thank MR4 for providing malaria parasite strains. We are indebted to Drs. Lalitha
471 Ramanathapuram, Patrick Sutton, Anna Maria van Eijk and all members of the CSCMi teams in
472 Delhi, Nadiad, Raurkela and Chennai for their support. Dr. Martina Bradic's help with the
473 linkage analysis is greatly appreciated. We also thank Dr. Neena Valecha and the staff of the
474 National institute of Malaria Research in Delhi, India for use of the facilities.

475 **Competing interests**

476 All authors have declared that no competing interests exist.

477 **Financial support**

478 This work was supported by the National Institute of Allergy and Infectious Diseases of the
479 National Institutes of Health under Award Number U19AI089676 as part of the International
480 Centers for Excellence in Malaria Research. The content is solely the responsibility of the
481 authors and does not necessarily represent the official views of the National Institutes of Health.

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502
503
504 **Tables**

505
506 Table 1: Sample summary and descriptive statistics
507

Category	Chennai	Nadiad	Raurkela	Total
Enrollment period	Dec 2012 - Oct 2014	Sep 2013 - Sep 2015	Mar 2013 - Nov 2014	N/A
No. of enrollees	15	41	85	141
Male	10	30	58	98
Female	5	11	27	43
Age range	13-50	13-60	2-69	2-69
Travel in last 14 days	2	7	11	20
No. of isolates	18	55	85	158
Microscopic	16	54	70	140
Submicroscopic	2	1	15	18
Average parasitemia (parasites/ul)	2867.56	9812.8	19202.82	10627.73
Clinic	14	39	21	74
Cross sectional	3	16	61	80
Other studies	1	0	3	4

508
509 Table 2: Frequency of haplotypes associated with drug resistance at three sites in India
510
511

Molecular Marker	Haplotype	Chennai	Nadiad	Raurkela	Predicted phenotype
PICRT	C V M N K	-	-	0.54	S
	S V M N I	1.00	0.93	0.02	RR
	C V I E I	-	0.04	0.33	RRR
	Unresolved	-	0.04	0.10	-
PIDHFR	A N C S I	0.11	0.11	0.34	S
	A N C <u>N</u> I	-	-	0.01	R
	A N <u>R</u> <u>N</u> I	0.89	0.82	0.45	RR
	Unresolved	-	0.07	0.20	-
PIDHPS	S A K A A	0.89	0.87	0.82	S
	S <u>Q</u> K A A	0.11	0.07	-	R
	S <u>G</u> <u>E</u> A A	-	-	0.01	RR
	<u>Δ</u> <u>G</u> <u>E</u> A A	-	-	0.02	RRR
	Unresolved	-	0.05	0.14	-
PIMDR1	N Y S N D	-	0.04	0.51	S
	Y Y S N D	-	0.20	0.13	R
	N E S N D	0.94	0.53	0.13	R
	N F S <u>D</u> D	-	-	0.01	RR
	Y E S N D	-	0.07	-	RR
	Unresolved	0.06	0.17	0.23	-

512
513
514


515 Table 3: Frequency of combination haplotypes associated with drug resistance at three sites in
 516 India
 517

Molecular Marker	Haplotype	Chennai	Nadiad	Raurkela
PICRT - P1MDRI	CVMNK-NYSND	-	-	0.39
	CVMNK-NESND	-	-	0.11
	CVMNK-YYSND	-	-	0.07
	SYMNI-NYSND	-	0.05	-
	SYMNI-NESND	1.00	0.66	0.02
	SYMNI-YYSND	-	0.20	0.02
	SYMNI-YESND	-	0.07	-
	CVIET-NYSND	-	-	0.23
	CVIET-NESND	-	-	0.05
	CVIET-NFSND	-	-	0.02
	CVIET-YYSND	-	0.02	0.10
	P1DHFR - P1DHPS	ANCSI-SAKAA	0.11	0.12
ANCI-SGEAA		-	-	0.02
ANCI-SAKAA		0.78	0.80	0.54
ANCI-SGKAA		0.11	0.08	-
ANCI-AGEAA		-	-	0.03

518
 519
 520
 521
 522


Figure Legends

523 Figure 1: Estimation of mixed genotypes using heterozygous variant calls.
 524 Plot showing number of high quality heterozygous variant calls (y-axis) for each *P. falciparum*
 525 clinical isolate. Isolates on the left of the vertical dotted line, which represents twice the median
 526 number of heterozygous variants observed in the entire dataset, were classified as potential
 527 mixed genotype infections.



528
 529
 530
 531
 532
 533
 534

Figure 2: Principal component analysis using high quality SNP data from all *P. falciparum* isolates. (A) Each isolate is colored by site (B) Each isolate is colored by site and shape denotes haplotype observed at PfCRT 72-76 locus. Unresolved refers to missing or partial data and mixed infection samples.



535
536
537
538

Supplementary Excel File

539 Supplementary Table 1: List of annotated, high-quality SNPs in six *P. falciparum* genes reported
540 by the Ion Torrent PGM Variant Caller Plugin
541 Supplementary Table 2: Data for follow-up patient samples showing key SNPs implicated in
542 drug resistance from six *P. falciparum* genes (represented as haplotypes).
543 Supplementary Table 3: High-quality SNPs in samples classified as potential multi-clonal
544 infections

545
546

REFERENCES

547

- 548
- 549 1. Wangdi, K., et al., *Malaria elimination in India and regional implications*. Lancet Infect
550 Dis, 2016. **16**(10): p. e214-24.
 - 551 2. WHO, *World Malaria Report 2016*. 2016.
 - 552 3. WHO, *World Malaria Report 2015- December 2015*. 2015.
 - 553 4. NVBDCP, *National Framework for Malaria Elimination in India 2016–2030*
 - 554 5. Shah, N.K., et al., *Antimalarial drug resistance of Plasmodium falciparum in India:
555 changes over time and space*. Lancet Infect Dis, 2011. **11**(1): p. 57-64.
 - 556 6. Rao, P.N., et al., *A Method for Amplicon Deep Sequencing of Drug Resistance Genes in
557 Plasmodium falciparum Clinical Isolates from India*. J Clin Microbiol, 2016. **54**(6): p.
558 1500-11.
 - 559 7. Das, A., et al., *Malaria in India: the center for the study of complex malaria in India*.
560 Acta Trop, 2012. **121**(3): p. 267-73.
 - 561 8. National Health Mission Tamil Nadu, D.o.H.a.F.W.; Available from:
562 <http://www.nrhmtn.gov.in/vbdc.html>.
 - 563 9. Anvikar, A.R., et al., *Antimalarial drug policy in India: Past, present & future*, in *Indian
564 J Med Res*. 2014. p. 205-15.
 - 565 10. Sidhu, A.B., D. Verdier-Pinard, and D.A. Fidock, *Chloroquine resistance in Plasmodium
566 falciparum malaria parasites conferred by pfcrt mutations*. Science, 2002. **298**(5591): p.
567 210-3.

- 568 11. Fidock, D.A., et al., *Mutations in the P. falciparum digestive vacuole transmembrane*
569 *protein PfCRT and evidence for their role in chloroquine resistance*. Mol Cell, 2000.
570 **6**(4): p. 861-71.
- 571 12. Djimde, A., et al., *Application of a molecular marker for surveillance of chloroquine-*
572 *resistant falciparum malaria*. Lancet, 2001. **358**(9285): p. 890-1.
- 573 13. Vathsala, P.G., et al., *Widespread occurrence of the Plasmodium falciparum chloroquine*
574 *resistance transporter (Pfcr) gene haplotype SVMNT in P. falciparum malaria in India*.
575 Am J Trop Med Hyg, 2004. **70**(3): p. 256-9.
- 576 14. Menard, D. and A. Dondorp, *Antimalarial Drug Resistance: A Threat to Malaria*
577 *Elimination*. Cold Spring Harb Perspect Med, 2017.
- 578 15. Cowman, A.F., et al., *Amino acid changes linked to pyrimethamine resistance in the*
579 *dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum*. Proc Natl
580 Acad Sci U S A, 1988. **85**(23): p. 9109-13.
- 581 16. Sirawaraporn, W., et al., *Antifolate-resistant mutants of Plasmodium falciparum*
582 *dihydrofolate reductase*. Proc Natl Acad Sci U S A, 1997. **94**(4): p. 1124-9.
- 583 17. Triglia, T., et al., *Allelic exchange at the endogenous genomic locus in Plasmodium*
584 *falciparum proves the role of dihydropteroate synthase in sulfadoxine-resistant malaria*.
585 EMBO J, 1998. **17**(14): p. 3807-15.
- 586 18. Brooks, D.R., et al., *Sequence variation of the hydroxymethyldihydropterin*
587 *pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria*
588 *parasite, Plasmodium falciparum, with differing resistance to sulfadoxine*. Eur J
589 Biochem, 1994. **224**(2): p. 397-405.
- 590 19. Straimer, J., et al., *Drug resistance. K13-propeller mutations confer artemisinin*
591 *resistance in Plasmodium falciparum clinical isolates*. Science, 2015. **347**(6220): p. 428-
592 31.
- 593 20. Ariey, F., et al., *A molecular marker of artemisinin-resistant Plasmodium falciparum*
594 *malaria*. Nature, 2014. **505**(7481): p. 50-5.
- 595 21. Dondorp, A.M., et al., *Artemisinin resistance in Plasmodium falciparum malaria*. N Engl
596 J Med, 2009. **361**(5): p. 455-67.
- 597 22. Menard, D., et al., *A Worldwide Map of Plasmodium falciparum K13-Propeller*
598 *Polymorphisms*. N Engl J Med, 2016. **374**(25): p. 2453-64.
- 599 23. Miotto, O., et al., *Genetic architecture of artemisinin-resistant Plasmodium falciparum*.
600 Nat Genet, 2015. **47**(3): p. 226-34.
- 601 24. Sisowath, C., et al., *In vivo selection of Plasmodium falciparum parasites carrying the*
602 *chloroquine-susceptible pfcr K76 allele after treatment with artemether-lumefantrine in*
603 *Africa*. J Infect Dis, 2009. **199**(5): p. 750-7.
- 604 25. Sisowath, C., et al., *In vivo selection of Plasmodium falciparum pfmdr1 86N coding*
605 *alleles by artemether-lumefantrine (Coartem)*. J Infect Dis, 2005. **191**(6): p. 1014-7.
- 606 26. Dokomajilar, C., et al., *Selection of Plasmodium falciparum pfmdr1 alleles following*
607 *therapy with artemether-lumefantrine in an area of Uganda where malaria is highly*
608 *endemic*. Antimicrob Agents Chemother, 2006. **50**(5): p. 1893-5.
- 609 27. Humphreys, G.S., et al., *Amodiaquine and artemether-lumefantrine select distinct alleles*
610 *of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for*
611 *uncomplicated malaria*. Antimicrob Agents Chemother, 2007. **51**(3): p. 991-7.

- 612 28. Sehgal, P.N.S., M. I. D.; Sharma, S. L.; Gogai, S., *Resistance to chloroquine in*
613 *falciparum malaria in Assam State, India.* . Journal of Communicable Diseases, 1973.
614 5(4): p. 175–180.
- 615 29. Saliba, K.J., P.I. Folb, and P.J. Smith, *Role for the plasmodium falciparum digestive*
616 *vacuole in chloroquine resistance.* Biochem Pharmacol, 1998. 56(3): p. 313-20.
- 617 30. Mehlotra, R.K., et al., *Evolution of a unique Plasmodium falciparum chloroquine-*
618 *resistance phenotype in association with pfcrt polymorphism in Papua New Guinea and*
619 *South America.* Proc Natl Acad Sci U S A, 2001. 98(22): p. 12689-94.
- 620 31. Mixson-Hayden, T., et al., *Evidence of selective sweeps in genes conferring resistance to*
621 *chloroquine and pyrimethamine in Plasmodium falciparum isolates in India.* Antimicrob
622 Agents Chemother, 2010. 54(3): p. 997-1006.
- 623 32. Mallick, P.K., et al., *Microsatellite analysis of chloroquine resistance associated alleles*
624 *and neutral loci reveal genetic structure of Indian Plasmodium falciparum.* Infect Genet
625 Evol, 2013. 19: p. 164-75.
- 626 33. Sutar, S.K., et al., *Sequence analysis of coding DNA fragments of pfcrt and pfmdr-1*
627 *genes in Plasmodium falciparum isolates from Odisha, India.* Mem Inst Oswaldo Cruz,
628 2011. 106(1): p. 78-84.
- 629 34. Kar, N.P., et al., *Comparative assessment on the prevalence of mutations in the*
630 *Plasmodium falciparum drug-resistant genes in two different ecotypes of Odisha state,*
631 *India.* Infect Genet Evol, 2016. 41: p. 47-55.
- 632 35. Sa, J.M., et al., *Geographic patterns of Plasmodium falciparum drug resistance*
633 *distinguished by differential responses to amodiaquine and chloroquine.* Proc Natl Acad
634 Sci U S A, 2009. 106(45): p. 18883-9.
- 635 36. Veiga, M.I., et al., *Globally prevalent PfMDR1 mutations modulate Plasmodium*
636 *falciparum susceptibility to artemisinin-based combination therapies.* Nat Commun,
637 2016. 7: p. 11553.
- 638 37. Ahmed, A., et al., *Plasmodium falciparum isolates in India exhibit a progressive increase*
639 *in mutations associated with sulfadoxine-pyrimethamine resistance.* Antimicrob Agents
640 Chemother, 2004. 48(3): p. 879-89.
- 641 38. Tun, K.M., et al., *Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a*
642 *cross-sectional survey of the K13 molecular marker.* Lancet Infect Dis, 2015. 15(4): p.
643 415-21.
- 644 39. Saha, P., et al., *Comparative efficacies of artemisinin combination therapies in*
645 *Plasmodium falciparum malaria and polymorphism of pfATPase6, pfcrt, pfdhfr, and*
646 *pfdhps genes in tea gardens of Jalpaiguri District, India.* Antimicrob Agents Chemother,
647 2012. 56(5): p. 2511-7.
- 648 40. Mishra, N., et al., *Declining efficacy of artesunate plus sulphadoxine-pyrimethamine in*
649 *northeastern India.* Malar J, 2014. 13: p. 284.
- 650 41. Mishra, N., et al., *Surveillance of artemisinin resistance in Plasmodium falciparum in*
651 *India using the kelch13 molecular marker.* Antimicrob Agents Chemother, 2015. 59(5):
652 p. 2548-53.
- 653 42. Mishra, N., et al., *Emerging polymorphisms in falciparum Kelch 13 gene in Northeastern*
654 *region of India.* Malar J, 2016. 15(1): p. 583.
- 655 43. Chatterjee, M., et al., *No Polymorphism in Plasmodium falciparum K13 Propeller Gene*
656 *in Clinical Isolates from Kolkata, India.* J Pathog, 2015. 2015: p. 374354.

- 657 44. Talundzic, E., et al., *Molecular Epidemiology of Plasmodium falciparum kelch13*
658 *Mutations in Senegal Determined by Using Targeted Amplicon Deep Sequencing.*
659 *Antimicrob Agents Chemother*, 2017. **61**(3).
- 660 45. Mohon, A.N., et al., *Mutations in Plasmodium falciparum K13 propeller gene from*
661 *Bangladesh (2009-2013).* *Malar J*, 2014. **13**: p. 431.
- 662 46. Torrentino-Madamet, M., et al., *Limited polymorphisms in k13 gene in Plasmodium*
663 *falciparum isolates from Dakar, Senegal in 2012-2013.* *Malar J*, 2014. **13**: p. 472.
- 664 47. Wang, Z., et al., *Prevalence of K13-propeller polymorphisms in Plasmodium falciparum*
665 *from China-Myanmar border in 2007-2012.* *Malar J*, 2015. **14**: p. 168.
- 666 48. Rahman, R., et al., *Continued Sensitivity of Plasmodium falciparum to Artemisinin in*
667 *Guyana, With Absence of Kelch Propeller Domain Mutant Alleles.* *Open Forum Infect*
668 *Dis*, 2016. **3**(3): p. ofw185.
- 669 49. Mideo, N., et al., *Ahead of the curve: next generation estimators of drug resistance in*
670 *malaria infections.* *Trends Parasitol*, 2013. **29**(7): p. 321-8.
- 671